Vivian has entered into a distribution agreement with worldwide R&D pharmaceutical company Novartis Pharma Services AG, a move that continues to reflect Vivian’s established reputation as a trusted partner for global life sciences brands.
The agreement will see Vivian manage the importation and distribution of various Novartis products in Malta, strengthening its role as a bridge between international pharmaceutical innovation and the local healthcare system.
According to Vivian’s Managing Director, Denise Borg Manche, this partnership reflects “The increasing confidence that global players are placing in Vivian’s robust regulatory setup, strong governance, and well-established infrastructure within Malta’s tightly regulated market.”
Over the years, Vivian has earned recognition for its operational excellence, compliance culture, and deep sectoral expertise. Its comprehensive structure allows international manufacturers to benefit from a seamless local presence, from logistics and supply chain management to regulatory affairs and market access.
“This agreement highlights the degree of trust multinational corporations are placing in Vivian,” said Borg Manche. “It reflects our continued investment in quality systems, people, and partnerships that bring world-class therapies closer to Maltese patients.”
“Novartis is broadening its distribution network in Malta through this partnership, confident that its products will continue to be supported by the highest operational and ethical standards,” according to Fabio Sperandei, Country President of Novartis Cyprus and Malta.
Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. In 2024, our medicines reach 296 million people worldwide.
Vivian’s General Manager, Yan Grima, added: “The distribution agreement follows a series of strategic partnerships that are strengthening Vivian’s position as a preferred partner for global healthcare brands seeking efficient and compliant entry into the Maltese market. It also reinforces Malta’s standing as a well-regulated, reliable hub for life sciences operations within the EU.”
